[Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
D000328:Adult; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D006834:Hydrazines; D004295:Dihydroxyphenylalanine
Fortschritte in den Behandlung des Parkinson-Syndroms mit L DOPA durch Kombination mit einem Decarboxylasehemmer. Ergebnisse einer Langzeitstudie.